1 Task Force Members, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003. doi:10.1093/eurheartj/eht296.
2 Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–619. doi:10.1093/eurheartj/ehs215.
3 Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315. doi:10.1093/eurheartj/ehv320.
4 Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016. doi:10.1002/ejhf.592.
5 Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–55. doi:10.1056/NEJM199605233342101.
6 Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–8. doi:10.1056/NEJM200105313442201.
7 Packer M. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study. Circulation. 2002;106:2194–9. doi:10.1161/01.CIR.0000035653.72855.BF.
8 Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295–302.
9 Flather MD, Shibata MC, Coats AJS, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–25. doi:10.1093/eurheartj/ehi115.
10 Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). The Lancet. 1999;353:2001–7. doi:10.1016/S0140-6736(99)04440-2.
11 The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. The Lancet. 1999;353:9–13. doi:10.1016/S0140-6736(98)11181-9.
12 European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GYH, Schotten U, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369–429. doi:10.1093/eurheartj/ehq278.
13 McNeill RS. Effect of a beta-adrenergic-blocking agent, propranolol, on asthmatics. The Lancet. 1964;2:1101–2.
14 Benson MK, Berrill WT, Cruickshank JM, Sterling GS. A comparison of four beta-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol. 1978;5:415–9.
15 J Lipworth B, A Williamson P. Think the impossible: β-blockers for treating asthma. Clin Sci. 2009;118:115–20. doi:10.1042/CS20090398.
16 Ind PW, Dixon CM, Fuller RW, Barnes PJ. Anticholinergic blockade of beta-blocker-induced bronchoconstriction. Am Rev Respir Dis. 1989;139:1390–4. doi:10.1164/ajrccm/139.6.1390.
17 Ponce González MA, Julià Serdà G, Santana Rodríguez N, Rodríguez Suárez P, Pérez Peñate G, Freixinet Gilart J, et al. Long-term pulmonary function after thoracic sympathectomy. J Thorac Cardiovasc Surg. 2005;129:1379–82. doi:10.1016/j.jtcvs.2004.08.026.
18 Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global Initiative for Asthma. Eur Respir J. 2008;31:143–78. doi:10.1183/09031936.00138707.
19 Fraunfelder FT, Barker AF. Respiratory effects of timolol. N Engl J Med. 1984;311:1441.
20 Morales DR, Dreischulte T, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blocker eye drops in asthma: population based study and meta-analysis of clinical trials. Br J Clin Pharmacol. 2016. doi:10.1111/bcp.13006.
21 Korte J-M, Kaila T, Saari MK. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefe’s Arch Clin Exp Ophthalmol. 2002;240:430–5. doi:10.1007/s00417-002-0462-2.
22 Rutten FH, Zuithoff NPA, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880–7. doi:10.1001/archinternmed.2010.112.
23 Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax. 2012;67:977–84. doi:10.1136/thoraxjnl-2012-201945.
24 Morales DR, Guthrie B, Lipworth BJ, Donnan PT, Jackson C. Prescribing of -adrenoceptor antagonists in asthma: an observational study. Thorax. 2011;66:502–7. doi:10.1136/thoraxjnl-2011-200067.
25 Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med. 2002;137:715–25.
26 Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blocker use in patients with reversible airway disease. Cochrane Database Syst Rev 2001:CD002992. doi:10.1002/14651858.CD002992.
27 Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse Respiratory Effect of Acute β-Blocker Exposure in Asthma. Chest. 2014;145:779–86. doi:10.1378/chest.13-1235.
28 Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomized Placebo-controlled Trial to Evaluate Chronic Dosing Effects of Propranolol in Asthma. Am J Respir Crit Care Med. 2013;187:1308–14. doi:10.1164/rccm.201212-2206OC.
29 Bond RA, Spina D, Parra S, Page CP. Getting to the heart of asthma: Can “β blockers” be useful to treat asthma? Pharmacology and Therapeutics 2007;115:360–74. doi:10.1016/j.pharmthera.2007.04.009.
30 Callaerts-Vegh Z, Evans KLJ, Dudekula N, Cuba D, Knoll BJ, Callaerts PFK, et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA. 2004;101:4948–53. doi:10.1073/pnas.0400452101.
31 Nguyen LP, Singh B, Okulate AA, Alfaro VY, Tuvim MJ, Dickey BF, et al. Complementary anti-inflammatory effects of a β-blocker and a corticosteroid in an asthma model. Naunyn Schmiedebergs Arch Pharmacol 2012;385:203–10. doi:10.1007/s00210-011-0692-0.